| # | Drug | Count |
|---|---|---|
| 0 | LEVOTHYROXINE SODIUM | 1148 |
| 1 | NIVOLUMAB | 1015 |
| 2 | PEMBROLIZUMAB | 928 |
| 3 | IPILIMUMAB | 599 |
| 4 | FUROSEMIDE | 589 |
| 5 | CARBOPLATIN | 584 |
| 6 | PREDNISONE | 498 |
| 7 | ATEZOLIZUMAB | 488 |
| 8 | ASPIRIN | 461 |
| 9 | LEVOTHYROXINE SODIUM ANHYDROUS | 456 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PROPYLTHIOURACIL | 140 | 0.0673 |
| 1 | METHIMAZOLE | 416 | 0.0520 |
| 2 | HETASTARCH | 6 | 0.0353 |
| 3 | AMIODARONE HYDROCHLORIDE | 365 | 0.0321 |
| 4 | POTASSIUM IODIDE | 45 | 0.0302 |
| 5 | SODIUM IODIDE I 131 | 23 | 0.0240 |
| 6 | SODIUM IODIDE I 123 | 20 | 0.0213 |
| 7 | ALEMTUZUMAB | 280 | 0.0145 |
| 8 | IPILIMUMAB | 599 | 0.0137 |
| 9 | IOMEPROL INJECTION | 19 | 0.0134 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 2335 |
| 1 | Corticosteroid [EPC] | 1298 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 984 |
| 3 | Platinum-based Drug [EPC] | 739 |
| 4 | Loop Diuretic [EPC] | 707 |
| 5 | Benzodiazepine [EPC] | 620 |
| 6 | CTLA-4-directed Blocking Antibody [EPC] | 619 |
| 7 | Proton Pump Inhibitor [EPC] | 571 |
| 8 | Kinase Inhibitor [EPC] | 539 |
| 9 | Thyroid Hormone Synthesis Inhibitor [EPC] | 523 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 81 | 0.1177 |
| 1 | Thyroid Hormone Synthesis Inhibitor [EPC] | 523 | 0.0536 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 2335 | 0.0237 |
| 3 | CD52-directed Cytolytic Antibody [EPC] | 280 | 0.0145 |
| 4 | CTLA-4-directed Blocking Antibody [EPC] | 619 | 0.0128 |
| 5 | Provitamin D2 Compound [EPC] | 322 | 0.0108 |
| 6 | Thyroid Stimulating Hormone [EPC] | 11 | 0.0106 |
| 7 | Sclerosing Agent [EPC] | 4 | 0.0089 |
| 8 | Programmed Death Ligand-1 Blocker [EPC] | 183 | 0.0085 |
| 9 | Guanylate Cyclase-C Agonist [EPC] | 16 | 0.0077 |